Caris Life Sciences Appoints Dave Fredrickson to Board

IRVING, Texas, Aug. 23, 2024 – Caris Life Sciences, a prominent player in the field of precision medicine and next-generation AI technology, has announced the appointment of Dave Fredrickson to its Board of Directors, effective August 15, 2024. Fredrickson, who currently serves as Executive Vice-President of the Oncology Business Unit at AstraZeneca PLC, expressed enthusiasm for Caris's mission, highlighting the company's innovative approach to providing patients with critical molecular-level insights into their diseases. Fredrickson brings a wealth of experience to the board, having held significant leadership roles within AstraZeneca, including President of AstraZeneca K.K. His academic background includes a Bachelor of Arts in Government from Georgetown University, which complements his extensive career in the pharmaceutical industry. His expertise is expected to bolster Caris's strategic direction as it continues to advance its precision medicine initiatives. Caris Life Sciences is dedicated to revolutionizing healthcare through the integration of sequencing technology, big data, and artificial intelligence. The company aims to develop cutting-edge tools for early detection, diagnosis, therapy selection, and drug development, thereby enhancing patient outcomes. Founded with a vision to harness the potential of precision medicine, Caris emphasizes its commitment to diversity and inclusion among its employees and patients. With operations spanning the U.S., Europe, Asia, and other international markets, Caris Life Sciences is poised to make significant strides in the healthcare sector. For more information, visit CarisLifeSciences.com.